Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET

Company Participants

Jill Steier - Executive Director, Investor Relations and Corporate Communications

Mark Iwicki - Chairman and Chief Executive Officer

Todd Bazemore - President and Chief Operating Officer

Kim Brazzell - Head of R&D and Chief Medical Officer

Mary Reumuth - Chief Financial Officer

Conference Call Participants

Christopher Neyor - JPMorgan

Francois Brisebois - Oppenheimer & Co.

Andreas Argyrides - Wedbush Securities

Operator

Good morning, and welcome to Kala Pharmaceuticals Conference Call to Review its First Quarter 2022 Financial Results. At this time, all participants are in a listen-only mode. Following management's prepared remarks, a Q&A session will be held. As a reminder, this call is being recorded.

I would now like to turn the call over to Jill Steier, Executive Director, Investor Relations and Corporate Communications for Kala Pharmaceuticals. Please proceed.

Jill Steier

Thank you, operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chief Executive Officer; Todd Bazemore, President and Chief Operating Officer; Kim Brazzell, Head of R&D and Chief Medical Officer; Mary Reumuth, Chief Financial Officer; and Darius Kharabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's call.

During this call, we will make certain comments about Kala's future expectations, plans and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include observations associated with our commercialization of EYSUVIS and INVELTYS, statements regarding the development program and market potential of KPI-012, and the sufficiency of our cash resources. These and other forward-looking statements are based on the beliefs and expectations of management as of this conference call. Our actual results may differ materially from our expectations.

The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances that occur after this conference call except as required by law.

Investors should carefully read the risks and uncertainties described in today's press release, as well as the risk factors which identifies specific factors that may cause actual results or events to differ materially from those described in our forward-looking statements, included in the company's quarterly report on Form 10-Q and other filings we made with the SEC.

I will now turn the call over to Kala's CEO, Mark Iwicki.

Mark Iwicki